Status:
COMPLETED
Intravenous Continuous LMWH Seems to Be Safe Alternative to UFH in VV ECMO Patients
Lead Sponsor:
University Hospital, Motol
Conditions:
Refractory Respiratory Failure
Eligibility:
All Genders
18+ years
Brief Summary
Unfractionated heparin (UFH) is worldwide anticoagulation used and recommended anticoagulation in patients with ECMO support. However, it is accompanied with incidence of bleeding or thrombotic compli...
Detailed Description
Unfractionated heparin (UFH) is worldwide anticoagulation used and recommended anticoagulation in patients with ECMO support. However, it is accompanied with incidence of bleeding or thrombotic compli...
Eligibility Criteria
Inclusion
- VV ECMO - use of 2 separate cannulas (jugular and femoral)
- anticoagulation with only intravenous continuous LMWH (Enoxaparin)
- only a period of the first ECMO set running
Exclusion
- pregnancy
- Avalon cannula (one double lumen cannula)
- patients after thoraco-abdominal surgery
- patients after lung transplantation in early postoperative period
- patients after trauma without any type of heparin ,,heparin free" ECMO
Key Trial Info
Start Date :
May 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 15 2023
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT06010446
Start Date
May 15 2019
End Date
August 15 2023
Last Update
February 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Unoversity Hospital Motol, Department of Anaesthesiology and Intensive Care
Prague, Czechia, 150 06